Halozyme Therapeutics, Inc. (HALO) — closed signal from September 21, 2025
Partial Published before the outcome was known, scored automatically when the window closed on December 20, 2025.
Predicted vs. what happened
What happened
Reached 13% of the predicted growth at its peak, without hitting the target.
The thesis — published September 21, 2025
Halozyme looks supported by big investors and the strength of its drug-delivery platform. Morgan Stanley lifted its target to 80 and Zacks calls it a Strong Buy, showing rising expectations. More partners are adopting ENHANZE, which boosts royalty income. The price setup looks healthy; buying near the recent average price makes sense, and a clear move above 80 could start a 3-month climb toward prior highs.
Primary drivers
- Morgan Stanley targets 80; Zacks rates it Strong Buy, boosting confidence
- More partners using ENHANZE increase royalty income and profit potential
- Price base looks healthy with an improving recent average price
- Platform earns fees and royalties, making growth scalable and predictable
How it played out
HALO: target was not reached
Lyra published HALO at 77.81 on 2025-09-21 with 17% expected growth. The thesis pointed to big-investor support, Morgan Stanley's 80 target, a Strong Buy rating from Zacks, wider ENHANZE adoption, royalty income, and a healthy price base near the recent average price.
Inside the window, HALO peaked at 79.5 on 2025-09-23, a 2.2% gain. It stayed below the 91.04 target and never reached it. By 2025-12-20, it ended at 67.35. The thesis did not play out on price, even though the stock briefly rose after publication.
What happened during the window
On November 3, 2025, Halozyme reported third-quarter results. Investors Business Daily later described it as a beat-and-raise quarter. On November 12, 2025, Investors Business Daily reported that HALO's Relative Strength Rating rose to 82.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.